Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic Steatohepatitis Is Associated With Liver‐Related Outcomes and All‐Cause Mortality in Chronic Hepatitis B
Hannah Choi, Willem Pieter Brouwer, Wayel M.R. Zanjir, et al.
Hepatology (2019) Vol. 71, Iss. 2, pp. 539-548
Closed Access | Times Cited: 166

Showing 26-50 of 166 citing articles:

NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
Piero Portincasa
Internal and Emergency Medicine (2023) Vol. 18, Iss. 4, pp. 993-1006
Open Access | Times Cited: 25
Development of a machine learning-based model to predict hepatic inflammation in chronic hepatitis B patients with concurrent hepatic steatosis: a cohort study
Fajuan Rui, Yee Hui Yeo, Liang Xu, et al.
EClinicalMedicine (2024) Vol. 68, pp. 102419-102419
Open Access | Times Cited: 11
AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases
Janani S. Iyer, Dinkar Juyal, Quang Le, et al.
Nature Medicine (2024) Vol. 30, Iss. 10, pp. 2914-2923
Open Access | Times Cited: 9
East Asia expert opinion on treatment initiation for chronic hepatitis B
Jia‐Horng Kao, Tsung‐Hui Hu, Jidong Jia, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 52, Iss. 10, pp. 1540-1550
Closed Access | Times Cited: 56
Chronic hepatitis B and non‐alcoholic fatty liver disease: Conspirators or competitors?
Jianbin Zhang, Shuang‐Zhe Lin, Daixi Jiang, et al.
Liver International (2020) Vol. 40, Iss. 3, pp. 496-508
Open Access | Times Cited: 55
Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
Ting Ting Chan, Wah‐Kheong Chan, Grace Lai‐Hung Wong, et al.
The American Journal of Gastroenterology (2020) Vol. 115, Iss. 6, pp. 867-875
Closed Access | Times Cited: 53
Epidemiology of non-alcoholic fatty liver disease in Asia
Sui‐Weng Wong, Wah‐Kheong Chan
Indian Journal of Gastroenterology (2020) Vol. 39, Iss. 1, pp. 1-8
Closed Access | Times Cited: 52
Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease
Shang‐Chin Huang, Hau-Jyun Su, Jia‐Horng Kao, et al.
Gut and Liver (2021) Vol. 15, Iss. 3, pp. 451-458
Open Access | Times Cited: 52
Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
Kyung‐Soo Kim, Sangmo Hong, Hong Yup Ahn, et al.
Diabetes & Metabolism Journal (2023) Vol. 47, Iss. 2, pp. 220-231
Open Access | Times Cited: 19
Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia
Ming Yang, Lai Wei
Liver International (2022) Vol. 42, Iss. 9, pp. 1981-1990
Closed Access | Times Cited: 23
Association Between the Presence of Metabolic Comorbidities and Liver-Related Events in Patients With Chronic Hepatitis B
Lesley A. Patmore, Warshan K. Katwaroe, Daniël P. C. van der Spek, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 12, pp. 3089-3096.e1
Open Access | Times Cited: 15
MAFLD and NAFLD in the prediction of incident chronic kidney disease
So Yoon Kwon, Jiyun Park, Sohee Park, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 14
Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B
Shang‐Chin Huang, Tung‐Hung Su, Tai‐Chung Tseng, et al.
The American Journal of Gastroenterology (2024)
Closed Access | Times Cited: 4
Prevalence and risk factors of significant Fibrosis in CHB patients with concurrent MASLD
Hong Shan, Yiwei Hao, Lei Sun, et al.
Annals of Hepatology (2024), pp. 101589-101589
Open Access | Times Cited: 4
Decanoylcarnitine improves liver mitochondrial dysfunction in hepatitis B virus infection by enhancing fatty acid β-oxidation
Ye Sun, Q L Chen, Yu-Xiao Liu, et al.
The Journal of Infectious Diseases (2025)
Closed Access
Update on the treatment navigation for functional cure of chronic hepatitis B: expert consensus 2.0
Di Wu, Jia‐Horng Kao, Teerha Piratvisuth, et al.
Clinical and Molecular Hepatology (2025)
Open Access
Prognostic and predictive effects of new steatotic liver disease nomenclatures: a large population‐based study
Huixian Zeng, Letian Fang, Zhiyu Yang, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access
Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B
Navavee Uman, Apichat Kaewdech, Pimsiri Sripongpun, et al.
Gastroenterology report (2025) Vol. 13
Open Access
The Association Between Metabolic Dysfunction‐Associated Steatotic Liver Disease and Change in Liver Stiffness in Patients With Chronic Hepatitis B
Lesley A. Patmore, Kirsi van Eekhout, Özgür M. Koc, et al.
Liver International (2025) Vol. 45, Iss. 3
Open Access
Impact of hepatic steatosis on mortality, hepatocellular carcinoma, end-stage liver disease and HBsAg seroclearance in chronic hepatitis B: a United States cohort study
George A. Yendewa, Abbinaya Elangovan, Temitope Olasehinde, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Regulation effects of rosemary (Rosmarinus officinalisLinn.) on hepatic lipid metabolism in OA induced NAFLD rats
Si-Jian Wang, Qian Chen, Meng-Yang Liu, et al.
Food & Function (2019) Vol. 10, Iss. 11, pp. 7356-7365
Closed Access | Times Cited: 37
Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion
Yiwen Shi, Rui‐Xu Yang, Jian‐Gao Fan
World Journal of Gastroenterology (2021) Vol. 27, Iss. 26, pp. 3971-3983
Open Access | Times Cited: 27
SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong
Chi‐Ho Lee, Lung‐Yi Mak, Eric Ho Man Tang, et al.
Hepatology (2023)
Closed Access | Times Cited: 11
Hepatitis B virus‐related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non‐viral risk factors
Wanying Li, Rui Deng, Shi Liu, et al.
Liver International (2020) Vol. 40, Iss. 10, pp. 2316-2325
Closed Access | Times Cited: 31
Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B
Mandana Khalili, David E. Kleiner, Wendy C. King, et al.
The American Journal of Gastroenterology (2021) Vol. 116, Iss. 8, pp. 1686-1697
Open Access | Times Cited: 26

Scroll to top